Trials / Recruiting
RecruitingNCT07308132
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) at the putative RP2D(s) (Part 2: Dose Expansion).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-95566692 | JNJ-95566692 will be administered subcutaneously. |
| DRUG | JNJ-87801493 | JNJ-87801493 will be administered subcutaneously. |
Timeline
- Start date
- 2026-01-20
- Primary completion
- 2028-08-31
- Completion
- 2028-08-31
- First posted
- 2025-12-29
- Last updated
- 2026-04-13
Locations
8 sites across 3 countries: Australia, Belgium, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07308132. Inclusion in this directory is not an endorsement.